[{"orgOrder":0,"company":"Avance Clinical","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Bugworks","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Bugworks","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Spinogenix","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Kither Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Actinogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"iQure Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"iQ-007","moa":"EAAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Vivani Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"GRIN Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"GRIN Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor| GRIN1|GRIN2B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Seismic Therapeutic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S-1117","moa":"IgG","graph1":"Undisclosed","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Seismic Therapeutic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Undisclosed","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"ADARx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Clinical \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Inimmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INI-4001","moa":"TLR","graph1":"Oncology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Inimmune","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"SignPath Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tafamidis","moa":"Transthyretin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"BioFactura","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BFI-751","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Parvus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PVT201","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"AP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AP601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2026","type":"Inapplicable","leadProduct":"OLX72021","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"}]
Find Clinical Drug Pipeline Developments & Deals by Avance Clinical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
